Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.

Natsubori T, Inoue H, Abe O, Takano Y, Iwashiro N, Aoki Y, Koike S, Yahata N, Katsura M, Gonoi W, Sasaki H, Takao H, Kasai K, Yamasue H.

Schizophr Bull. 2014 Sep;40(5):1128-39. doi: 10.1093/schbul/sbt124. Epub 2013 Sep 10.

2.

T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia.

Bracken BK, Rouse ED, Renshaw PF, Olson DP.

Psychiatry Res. 2013 Aug 30;213(2):142-53. doi: 10.1016/j.pscychresns.2013.03.005. Epub 2013 Jun 12. Review.

3.

Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis.

Kraguljac NV, Reid M, White D, Jones R, den Hollander J, Lowman D, Lahti AC.

Psychiatry Res. 2012 Aug-Sep;203(2-3):111-25. doi: 10.1016/j.pscychresns.2012.02.003. Epub 2012 Sep 13. Review.

4.

Clinical and cognitive correlates of the proton magnetic resonance spectroscopy measures in chronic schizophrenia.

Szulc A, Galińska-Skok B, Tarasów E, Konarzewska B, Waszkiewicz N, Hykiel R, Walecki J.

Med Sci Monit. 2012 Jun;18(6):CR390-8.

5.

Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?

Allen PJ.

Neurosci Biobehav Rev. 2012 May;36(5):1442-62. doi: 10.1016/j.neubiorev.2012.03.005. Epub 2012 Mar 24. Review.

6.

Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia.

Seese RR, O'Neill J, Hudkins M, Siddarth P, Levitt J, Tseng B, Wu KN, Caplan R.

Schizophr Res. 2011 Dec;133(1-3):82-90. doi: 10.1016/j.schres.2011.07.011. Epub 2011 Aug 27.

7.

Magnetic resonance spectroscopy of limbic structures displays metabolite differences in young unaffected relatives of schizophrenia probands.

Capizzano AA, Toscano JL, Ho BC.

Schizophr Res. 2011 Sep;131(1-3):4-10. doi: 10.1016/j.schres.2011.05.024. Epub 2011 Jun 25.

8.

Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis.

de la Fuente-Sandoval C, León-Ortiz P, Favila R, Stephano S, Mamo D, Ramírez-Bermúdez J, Graff-Guerrero A.

Neuropsychopharmacology. 2011 Aug;36(9):1781-91. doi: 10.1038/npp.2011.65. Epub 2011 Apr 20.

9.

Very early onset and greater vulnerability in schizophrenia: A clinical and neuroimaging study.

Margari F, Presicci A, Petruzzelli MG, Ventura P, Di Cuonzo F, Palma M, Margari L.

Neuropsychiatr Dis Treat. 2008 Aug;4(4):825-30.

10.

Neuroimaging studies of normal brain development and their relevance for understanding childhood neuropsychiatric disorders.

Marsh R, Gerber AJ, Peterson BS.

J Am Acad Child Adolesc Psychiatry. 2008 Nov;47(11):1233-51. doi: 10.1097/CHI.0b013e318185e703. Review.

11.

Magnetic resonance imaging and spectroscopy in a mouse model of schizophrenia.

Torres G, Hallas BH, Gross KW, Spernyak JA, Horowitz JM.

Brain Res Bull. 2008 Mar 28;75(5):556-61. doi: 10.1016/j.brainresbull.2007.09.006. Epub 2007 Oct 17.

12.

Reduced N-acetyl-aspartate levels in schizophrenia patients with a younger onset age: a single-voxel 1H spectroscopy study.

Stanley JA, Vemulapalli M, Nutche J, Montrose DM, Sweeney JA, Pettegrew JW, MacMaster FP, Keshavan MS.

Schizophr Res. 2007 Jul;93(1-3):23-32. Epub 2007 May 10.

13.

Cortical gray matter differences identified by structural magnetic resonance imaging in pediatric bipolar disorder.

Frazier JA, Breeze JL, Makris N, Giuliano AS, Herbert MR, Seidman L, Biederman J, Hodge SM, Dieterich ME, Gerstein ED, Kennedy DN, Rauch SL, Cohen BM, Caviness VS.

Bipolar Disord. 2005 Dec;7(6):555-69.

Supplemental Content

Support Center